4D Molecular Therapeutics, Inc.·4

Jan 25, 4:59 PM ET

Kirn David 4

4 · 4D Molecular Therapeutics, Inc. · Filed Jan 25, 2024

Insider Transaction Report

Form 4
Period: 2024-01-23
Kirn David
DirectorChief Executive Officer
Transactions
  • Sale

    Common Stock

    2024-01-23$18.41/sh5,696$104,8511,151,154 total
Footnotes (2)
  • [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.
  • [F2]The transaction was executed in multiple trades in prices ranging from $18.06 to $18.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4